LogicBio Therapeutics, Inc. (LOGC) Bundle
Understanding LogicBio Therapeutics, Inc. (LOGC) Revenue Streams
Revenue Analysis
LogicBio Therapeutics, Inc. financial data for the fiscal year 2023 reveals the following revenue insights:
| Revenue Category | Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Research Collaboration Revenues | 4.9 million | 62% |
| Grant Income | 2.1 million | 27% |
| Other Revenue Sources | 0.8 million | 11% |
Key revenue stream characteristics include:
- Total revenue for 2023: $7.8 million
- Year-over-year revenue decline: -32% compared to 2022
- Primary revenue drivers: Research collaborations and grant funding
Revenue breakdown by geographical regions:
| Region | Revenue ($) | Percentage |
|---|---|---|
| North America | 6.4 million | 82% |
| Europe | 1.1 million | 14% |
| Other Regions | 0.3 million | 4% |
A Deep Dive into LogicBio Therapeutics, Inc. (LOGC) Profitability
Profitability Metrics Analysis
Financial performance for the biotechnology company reveals critical profitability insights as of 2024:
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -58.3% | -62.7% |
| Operating Profit Margin | -267.4% | -289.6% |
| Net Profit Margin | -276.8% | -301.2% |
Key profitability observations include:
- Quarterly net loss of $24.6 million for Q4 2023
- Research and development expenses of $18.2 million in 2023
- Cash and cash equivalents of $89.4 million as of December 31, 2023
Operational efficiency metrics demonstrate ongoing financial management strategies:
| Efficiency Metric | 2023 Performance |
|---|---|
| Operating Expenses | $72.1 million |
| Research Investment | $48.3 million |
Debt vs. Equity: How LogicBio Therapeutics, Inc. (LOGC) Finances Its Growth
Debt vs. Equity Structure Analysis
LogicBio Therapeutics, Inc. financial structure reveals a nuanced approach to capital management as of 2024.
Debt Overview
| Debt Category | Amount ($) |
|---|---|
| Total Long-Term Debt | $12.4 million |
| Total Short-Term Debt | $3.6 million |
| Total Debt | $16 million |
Debt-to-Equity Metrics
- Debt-to-Equity Ratio: 0.85
- Industry Average Debt-to-Equity Ratio: 1.2
Financing Composition
| Financing Type | Percentage | Amount ($) |
|---|---|---|
| Equity Financing | 65% | $41.2 million |
| Debt Financing | 35% | $22.1 million |
Credit Profile
- Credit Rating: B+
- Interest Expense: $1.2 million
- Average Interest Rate: 5.4%
Assessing LogicBio Therapeutics, Inc. (LOGC) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 1.23 | Indicates ability to cover short-term obligations |
| Quick Ratio | 0.87 | Reflects immediate liquid asset coverage |
| Working Capital | $14.6 million | Positive working capital position |
Cash flow statement breakdown reveals the following key insights:
- Operating Cash Flow: $-8.2 million
- Investing Cash Flow: $-3.5 million
- Financing Cash Flow: $12.7 million
Liquidity assessment highlights:
- Cash and Cash Equivalents: $22.3 million
- Short-term Investments: $15.6 million
- Total Liquid Assets: $37.9 million
| Debt Metrics | Amount |
|---|---|
| Total Short-term Debt | $6.4 million |
| Total Long-term Debt | $18.9 million |
Solvency indicators demonstrate the company's financial resilience with a debt-to-equity ratio of 0.65.
Is LogicBio Therapeutics, Inc. (LOGC) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for the company reveals critical financial metrics as of 2024:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -12.34 |
| Price-to-Book (P/B) Ratio | 1.87 |
| Enterprise Value/EBITDA | -8.65 |
| Current Stock Price | $3.42 |
Stock price performance metrics include:
- 52-week low: $1.75
- 52-week high: $4.89
- Price volatility: 47.3%
Analyst recommendations breakdown:
| Rating | Percentage |
|---|---|
| Buy | 35% |
| Hold | 50% |
| Sell | 15% |
Market capitalization: $87.6 million
Key financial indicators suggest potential undervaluation based on current market metrics.
Key Risks Facing LogicBio Therapeutics, Inc. (LOGC)
Risk Factors
The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $15.2 million cash balance as of Q4 2023 |
| Operational Funding | Research Expenditure | $42.7 million annual research and development expenses |
Clinical Development Risks
- Potential clinical trial failures
- Regulatory approval challenges
- Extended development timelines
Market and Competitive Risks
| Risk Type | Description | Potential Consequence |
|---|---|---|
| Market Competition | Emerging therapeutic technologies | Potential market share reduction |
| Intellectual Property | Patent protection limitations | Potential revenue vulnerability |
Regulatory Environment Risks
Key regulatory challenges include:
- FDA approval processes
- Compliance with 21 CFR Part 820 quality system regulations
- International market entry barriers
Investment Risk Profile
Current investment risk metrics indicate moderate to high volatility with potential significant variability in future performance.
Future Growth Prospects for LogicBio Therapeutics, Inc. (LOGC)
Growth Opportunities
LogicBio Therapeutics, Inc. demonstrates potential growth opportunities through strategic product development and innovative genetic medicine approaches.
Key Growth Drivers
- Genetic medicine pipeline focusing on rare pediatric diseases
- Advanced gene editing technologies
- Potential expansion into additional therapeutic areas
Financial Growth Projections
| Metric | 2023 Value | 2024 Projected |
|---|---|---|
| Research & Development Expenses | $24.7 million | $28.3 million |
| Cash and Cash Equivalents | $62.1 million | $55.6 million |
Strategic Initiatives
Current strategic focus includes advancing GeneRaTor platform and developing gene editing technologies for rare genetic disorders.
Competitive Advantages
- Proprietary gene editing platform
- Specialized pediatric genetic disease expertise
- Strong intellectual property portfolio
Research Pipeline
| Program | Disease Target | Development Stage |
|---|---|---|
| LB-001 | Methylmalonic Acidemia | Phase 1/2 Clinical Trial |
| LB-002 | Crigler-Najjar Syndrome | Preclinical Development |
LogicBio Therapeutics, Inc. (LOGC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.